Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Exclusion Criteria

• •1. Pregnant or breastfeeding women
• •2. History of chronic disease (other than AD or EoE) requiring therapy (eg, heart disease, diabetes, hypertension) that, in the opinion of the principal investigator, would represent a risk to the participant's health or safety in this study or the participant's ability to comply with the study protocol. Participants on DUPIXENT for conditions other than AD or EoE (eg, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, etc) are excluded
• •3. Known or suspected progressive multifocal leukoencephalopathy (PML), or history of PML, neurodegenerative condition, central nervous system (CNS) movement disorder, or seizure within 12 months prior to Day 1
• •4. Recent history (within past 30 days) of a grade 3 or grade 4 gastrointestinal bleed, history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation
• •5. History of moderate or severe asthma based on the Global Initiative for Asthma (GINA) guidelines
• •6. Pre-bronchodilator forced expiratory volume in the first second (FEV1) \<80% of predicted using local reference values
• •7. Any prior exposure to a B-cell maturation antigen (BCMA) targeted therapy
• •8. Use of systemic corticosteroids within 2 months prior to screening
• •9. Use of other forms of allergen immunotherapy (eg, oral, SC, patch, or sublingual) or immunomodulatory therapy (not including corticosteroids) within 4 months prior to screening
• •10. Unwilling to discontinue use of antihistamines within 5 days prior to screening and within 5 days prior to skin prick test (SPT)
• •11. Hypersensitivity to epinephrine and any of the excipients in the epinephrine product
• •12. Within the previous 2 months of the screening visit has a history of bacterial, protozoal, viral or parasite infection requiring hospitalization or treatment with IV anti-infectives
• •13. Known history of human immunodeficiency virus (HIV) infection or HIV seropositivity at the screening visit